Related Experiment Video
Updated: Jun 17, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Current progress in targeted therapy for colorectal cancer.
Jose Ortega1, Carlos E Vigil, Catherine Chodkiewicz
1Gastrointestinal Tumor Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Cancer Control : Journal of the Moffitt Cancer Center
|December 17, 2009
Summary
Targeted therapies like bevacizumab and EGFR inhibitors are used for colorectal cancer, but combinations may increase toxicity. Further research is needed to identify predictive markers and optimize treatment strategies for better patient selection.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Colorectal cancer treatment involves several molecular targeting agents, with many more in clinical development.
- Current therapeutic options include angiogenesis inhibitors and epidermal growth factor receptor (EGFR) inhibitors.
Purpose of the Study:
- To review the biology and clinical use of approved targeted agents for colorectal cancer.
- To present data on emerging tyrosine kinase inhibitors in clinical trials.
- To discuss predictive testing and optimize treatment strategies.
Main Methods:
- Literature review of approved and investigational targeted therapies for colorectal cancer.
- Analysis of current clinical trial data for newer agents.
- Synthesis of information on drug interactions, resistance mechanisms, and treatment sequencing.
Main Results:
- Bevacizumab (angiogenesis inhibitor), cetuximab, and panitumumab (EGFR inhibitors) are approved for colorectal cancer.
- Combined use of bevacizumab and EGFR inhibitors may increase toxicity and reduce efficacy.
- Understanding of drug resistance and optimal sequencing with other modalities requires further investigation.
Conclusions:
- Identification of predictive response markers is critical for patient selection.
- Understanding potential negative interactions between targeted agents is essential.
- Refining the optimal use and sequencing of targeted therapies with surgery and other treatments is necessary.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...